|
[1]Robak T, Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther.2009 Sep;31(2):2349-70. [2]Danial G.T. Disruption of differentiation in human cancer: AML shown the way. Nat Rev Cancer 2003 Feb;3(2):89-01 [3]Margaret R, O’Donnell, MD.Acute Leukemias. Cancer Management:14th [4]Lanba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74 [5]Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011 Feb;29(5):487-94 [6]Galmarini CM, Cros E, Thomas X, Jordeheim L, Dumontet C. The prognostic value of cN-II and cN-III enzymes in adult acute myeloid leukemia. Haemotologica,2005 Dec;90(12):1699-01 [7]Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerinik JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ,Pieters R, Kaspers GJ. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivy in childhood acute myeloid leukaemia. Br J Cancer.2005 Dec;93(12):1388-98 [8]Veuger MJ, Honders MW, Spoelder HE, Willemze R, Barge RM. Inactivation of deoxycytidine kinase and overexpression of P-glycopreotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res.2003 May;27(5):445-53 [9]Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer.2004 Oct;4(10):793-05 [10]Prives C, Hall PA. The p53 pathway. J Pathol.1999 Jan;187(1):112-26 [11]Zhan Q, Antinore MJ, Wang XW. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45. Oncogene.1990 May;18(18):2892-00 [12]Liversey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC,Zhang L, Manfredi JJ, Zeh HJ 3rd, Li L, Lotze MT, Tang D. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res.2012 Apr;72(8):1996-05 [13]Shen L, Sun X, Fu Z, Yang G, Li J, Yao L. The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res.2012 Mar;18(6):1561-07 [14]CR Boland, MF Lucianni C Gasche, A Goel. Infection, inflammation and gastrointenstinal cancer. Gut.2005 Sep;54(9):1321-31 [15]Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev.2012 Jun;26(12):1268-86 [16]Gaidano G, Ballerini P, Gong JZ. P53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA.1991 Jun;88(12):5413-07 [17]H Ahuja, M Bar-Eli,Z Arlin, S Advani, S L Allen, J Goldman, D Snyder, A Foti, M Cline. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest.1991 Jun;87(6):2042-07 [18]Fenaux P, Preudhomme C, Lai JL, Quiquandaon I, Jonveaux P, Vanrumbeke M, Sartiaux C, Morel P, Loucheux-Lefebvre MH, Bauters F. Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia.1992 Apr;6(4):246-50 [19]Fenaux P, Jonveaux P, Quiquandon L, Lai JL, Pignon JM, Loucheux-Lefebyre MH, Bauters F, Berger R, Kerckaert JP. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood.1991 Oct;78(7):1652-07 [20]Di Agaostino S, Strano S, Emillozzi V, Zerbine V, Mottolese M, Sacchi A, Blandino G, Piaggio G. Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer cell.2006 Sep:10(3):191-02 [21]Wattel E, Preudhomme c, Hecquet B, Vanrumbeke M, Quesnel B, Derivite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood.1994 Nov;84(9):3148-57 [22]Yin B, Kogan SC, Dickins RA, Lowe Sw, Largaespada DA. Trp53 loss during in vitro selection contributes to acquired Ara-C resistance in acute myeloid leukemia. Exp Hematol.2006 May;34(5):631-41 [23]Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood.2002 Sep;100(5):1532-42 [24]Williams AB, Li L, Nguyen B, Brown P, Levis M, Small D. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood.2012 Oct;120(15):3069-79 [25]Hayakawa F, Towatari M, Kiyoi H, Tanimoto M,Kitamura T, Saito H, Naoe T. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3 dependent cell lines. Oncogene.2000 Feb;19(5):624-31 [26]Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishirumura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R,Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood.2001 Apr;97(8):2434-39 [27]Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncology Reviews.2012 Apr;6(8):65-74 [28]Jin G, Matsushita H, Asai S, Tsukamoto H,Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H. FLT3-ITD induces ara-c resistance in myeloid leukemia cells through the repression of the ENT1 expression. Biochem Biophys Res Commum.2009 Dec;390(3):1001-06 [29]Wang L, Yang CP, Horwitz SB, Trail PA, Casazza AM. Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. J Cancer Chemotherapy Pharmocol.1994 Jan;34(2):96-02 [30]Mannsson E, Paul A, Lofgen C, Ullberg K, Paul C, Eriksson S, Albertioni F. Cross-resistance to cytosine arabinoside in a multidrug-resistance human promyelocytic cell line selected for resistance to doxorubicin:implications for combination chemotherapy. Br J Haematol.2001 Sep;114(3):557-65 [31]Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promoter of the human mdr1 gene by Ras and p53. J Science.1992 Jan;255(5043):459-62 [32]Legrand O, Zittoun R, Marie JP. Role of MRP1 in multidrug resistance in acute myeloid leukemia. Leukemia.1999 Apr;13(4):578-84 [33]Sonneveld P, Peiters R. The prognostic significance of membrane transport associated multidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther.2000 Mar;38(3):94-10 [34]Borg AG, Burgess R, Green LM, Scheper RJ, Liu Yin JA. P-glycoprotein and multidrug resistance associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myleloid leukemic cells. Br J Haematol.2000 Jan;108(1):48-54 [35]Zhou P, Qian L, Craig RW. Mcl-1. a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood.1997 Jan;89(2):630-43 [36]Kasper S, Breitenbuecher F, HeideI F, Hoffarth S, Markova B, Schuler M, Fischer T. Targeting Mcl-1 sensitizes FLT3-ITD positive leukemias to cytotoxic therapies. Blood Cancer J.2012 Mar;2(3):e60. [37]McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta,2007 Aug;1773(8):1263-84 [38]VL Grandage, RE Gale, DC Linch, A Khwaja. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways. Leukemia.2005 Feb;10(1038):,586-94 [39]Blume-Jensen P, Hunter T. Oncogenic kinase signaling. Nature.2001 May;411(6835):355-65 [40]Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene.2000 Nov;19(49):5548-57 [41]Robertson SC, Tynan JA, Donoqhue DJ. RTK mutations and human syndromes when good receptors turn bad. Trends Genet.2000 Jun;16(6):265-71 [42]Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett.2008 Sep;226(2):314-24 [43]O’Bryan JP, Frye RA, Coqswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R 3rd, Le Beau MM, Earp HS, Liu ET. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encoded a novel receptor tyrosine kinase. Mol Cell Biol.1991 Oct;11(10):5016-31 [44]Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol.2003 Aug;22(8):533-40 [45]Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, Kanda N, Sekikawa A, Fukui H, Yanagita M, Yoshibayashi H, Satoh S, Sakai Y, Nakano T, Chiba T. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog.2007 Feb;46(2):155-64 [46]Shieh YS, Lai CY, KaoYR,Shiah SG, Chu YW, Lee HS, Wu CW. Expression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression. Neoplasia.2005 Dec;7(12):1058-64 [47]Sun W, Fujimoto J, Tamaya T. Coexpression of Gas6/Axl in human ovarian cancers. Oncology.2004 Sep;66(6):450-57 [48]Benzakour O, Gely A, Lara R, Coronas V. Gas-6 and protein S : vitamin K-dependent factors and ligands for the TAM tyrosine kinase receptors family. Med Sci(Paris).2007 Oct;23(10):826-33 [49]Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, Mizuno K. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky and Mer receptor tyrosine kinases. J Biol Chem.1996 Nov;271(47):300322-27 [50]Linger RM, Keating AK, Earp HS, Graham DK. TAM Receptor Tyrosine Kinase: Biologic Functions, Signaling and Potential TherapeaticTargeting in Human Cancer. Adv Cancer Res.2008 Jul;10(100):35-83 [51]Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1,Sp3 and CpG methylation. Biosci Rep.2008 Jun;28(3):161-76 [52]Hermeking H. MicroRNAs in the p53 network: micromanagement of tumor suppression. Nat Rev Cancer.2012 Sep;12(9):612-26 [53]Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S. Gain-of-Function activity of mutant p53 in Lung Cancer through up-regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer.2012 Jul;3(708):491-02 [54]Hasanbasic I, Cuerguis J, Varnum B, Blostein MD.Intracellular signaling pathways involved in Gas6-Axl mediated survival of endothelial cells. AM J Physiol Heart Circ Physiol. 2004 Sep;287(3):1207-13 [55]Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappaB and Brg-1. Oncogene.2008 Jul;27(29):4044-55 [56]Reed JC. Bcl-2 family proteins : regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol.1997 Oct,34(4):9-19 [57]Anker L, Ohgaki H, Ludeke BI, Herrmann HD, Kleihues P, Westphal M. p53 protein accumulation and gene mutations in human glioma cell lines. Int J Cancer.1993 Dec;55(6):982-87 [58]Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH. Cabozantinib(XL184),a novel MET and VEGFR2 inhibitor, stimultaneously suppresses metastasis, angiogenesis and tumor growth. Mol Cancer Ther.2011 Dec;10(19):2293-08 [59]Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y. R428, a selective small molecule inhibitor of Axl kinase,blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res.2010 Feb;70(4):1544-54 [60]Yoshimoto G,Miyamoto T,Jabbarzadeh-Tabrizi S, lino T, Rocnik JL,Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka Km Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K. FLT3-ITD up-regulates Mcl-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood.2009 Dec;114(24):5034-43 [61]Lippert TH, Ruoff HJ, Volm M. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung.2008 Jun;58(6):261-64 [62]Di Bona E, Sartori R, Zambello R, Gurecini N, Madeo D, Rodeghiero F. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.Haematologica.2002 Mar;87(3):250-56 [63]Raspadorii D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F. CD56 antigenic expression in acute myeloid leukemia: impact on clinical outcome. Leukemia.2001 Aug;15(8):1161-64 [64]Raspadorii D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome. Hematologica.2002 Nov;87(11):1135-40 [65]Suvannasankha A, Minderman H, Sait SN, Stewart CC, Greco WR, Baer MR. Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. Leuk Res.2004 May;28(5):449-55 [66]Mathiot C, Teillaud JL, Elmalek M, Mosseri V, Euller-Ziegler L, Daragon A, Grosbois B, Michaux JL, Facon T, Bernard JF. Correlation between soluble serum CD16(sCD16) levels and disease stage in patients with multiple myeloma. J Clin Immunol.1993 Jan;13(1):41-48 [67]Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration bu FcγRII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer.2011 Jun;128(11):2663-72 [68]Termijtelen A, van Lewuwen A, van Rood JJ . HLA-linked lymphocyte activating determinants. Immunol Rev.1982 Sep;66(1):79-01 [69]Brian A Webber, Melissa M Cushing, Shiyong Li. Prognostic Significance of Flow Cytometric Immunophenotyping in Acute Myeloid Leukemia. Int J Clin Exp Pathol.2008 Jan;1(2):124-33 [70]Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2’deoxycytidine. Lancet.1984 Oct;2(8407):867-68 [71]Han LN, Zhou J, Schuringga JJ, Vellenga E. Treatment strategies in acute myeloid leukemia. Chin Med J (Engl).2011 May;124(9):1409-21 [72]Materlli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling netweork as a therapeutic target in acute myelogenous leukemia patiens. Oncotarget.2010 Jun;1(2):89-03 [73]Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood.2002 Sep;100(5):1532-42 [74]Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PN, Bohmer FD, Gerke V, Schmidt-Arras DE, Berdel WE, Muller-Tidow C, Mann M, Serve H. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell.2009 Oct;36(2):326-39 [75]Yoshimoto G, Miyaomoto T, Jabbarzadeh TS, lino T, Rocknik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K. FLT3-ITD up-regulates Mcl-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood.2009 Dec;114(24):5034-43 [76]Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol. 1999 Sep;19(9):6195-06 [77]Liu H, Ma Y, Cole SM, Zander C, Chen KH, Karras J, Pope RM. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood.2003 Jul;102(1):344-52 [78]Liu XH, Yu EZ, Li YY, Kagan E. HIF-1 aplha has an-anti-apoptotic effect in human airway epithelium that is mediated via Mcl-1 gene expression. J Cell Biochem.2006 Mar;97(4):755-65 [79]Inuzuka H, Fukushima H, Shaik S,Liu P, Lau AW, Wei W. Mcl-1 ubiquitination and destruction. Oncotarger.2011 Mar;2(3):239-44 [80]Leisewitz AV, Zimmeraman EI, Huang M, Jones SZ, Yang J, Graves LM. Regulation of ENT1 expression and ENT1-dependent nucleoside transport by c-Jun-N-terminal kinase. Biochem Biophys Res Commun.2011 Jan;404(1):370-75 [81]Jin G, Matsuhita H, Asai S, Tsukamoto H, Ono R, Nosaka T, Yahata T, Takahashi S, Miyachi H. FLT3-ITD induced ara-c resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun. 2009 Dec;390(3);1001-06 [82]Brooks CL, Gu W. Ubiquitionation, phosphorylation and acetylation : the molecular basis for p53 regulation. Curr Opin Cell Biol. 2003 Apr;15(2):164-71 [83]Toledo F, Wahi GM. Regulating the p53 pathawy: in vitro hypothese, in vivo veritas. Nat Rev Cancer.2006 Dec;6(12):909-23 [84]Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci.2012 May;8(5):672-84 [85]Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012 Jun;26(12):1268-86 [86]Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. Intracellular signaling pathways involved in Gas6-Axl mediated survival of endothelial cells. Am J physiol Heart Circ Physiol.2004 Sep;287(3):H1207-13 [87]Sato T, Yang T, Knapper S, White P, Smith BD, Galkin S, Small D, Burnett A, Lewis M. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood.2011 Mar;117(12):3286-93 [88]Song JH, Kim SH, Kim HJ, Hwang SY, Kim TS. Alleviation of the drug resistant phenotype in idarubicing and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin. Int J Oncol.2008 Apr;32(4):931-36 [89]Dartsch DC, Gieseler F. Repair of idarubicin-induced DNA damage: a cause of resistance? DNA Repair(Amst).2007 Nov;6(11):1618-28
|